Logistic regression analysis for predicting the likelihood of patients requiring additional topical steroids while being treated with topical ciclosporin/Ikervis (total n=387 patients). Patients who were intolerant to the Ikervis were excluded from this analysis
| Parameters | OR (95% CI) | P value |
| Age, years | 0.04 | |
| 0–18 | 0.62 (0.12 to 3.19) | 0.56 |
| >18 to 30 | 3.02 (0.86 to 10.61) | 0.09 |
| >31 to 50 | 0.44 (0.13 to 1.55) | 0.2 |
| >51 to 70 | 1.59 (0.64 to 3.94) | 0.32 |
| >70 | Reference | – |
| Gender | ||
| Female | 0.78 (0.37 to 1.65) | 0.52 |
| Male | Reference | – |
| Indications | <0.001 | |
| Dry eye disease | Reference | – |
| AED | 9.18 (3.01 to 27.94) | <0.001 |
| OMMP/SJS | 0.90 (0.19 to 4.18) | 0.89 |
| Post-keratoplasty | 9.59 (2.66 to 34.57) | 0.001 |
| Others | 1.27 (0.34 to 4.78) | 0.72 |
| Treatment frequency | 0.016 | |
| Once a day | Reference | – |
| Twice a day | 2.86 (1.39 to 5.90) | 0.04 |
| >Twice a day | 3.19 (0.29 to 35.25) | 0.34 |
AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic keratoconjunctivitis; OMMP, ocular mucous membrane pemphigoid; SJS, Steven-Johnson syndrome.